The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery

Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational study

(2014) Sixten Selleng et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Inhibition of platelet activation could decrease thrombotic events in hemodialysis PF4/H antibody-positive patients

(2014) Yang Yang et al.   RENAL FAILURE

Differences in the clinical course of heparin induced thrombocytopenia before and after the availability of HIT IgG class testing

(2014) John L. Reagan et al.   THROMBOSIS RESEARCH

How I treat heparin-induced thrombocytopenia

(2012) A. Cuker et al.   BLOOD

Treatment and Prevention of Heparin-Induced Thrombocytopenia

(2012) Lori-Ann Linkins et al.   CHEST

Heparin-Induced Thrombocytopenia After Cardiac Surgery: An Observational Study of 1,722 Patients

(2012) Pascale Piednoir et al.   JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA

2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery

(2011) et al.   CIRCULATION

Anti-PF4/heparin antibodies are associated with arteriovenous fistula thrombosis in non-diabetic hemodialysis patients

(2011) Yueh-Feng Tsai et al.   Clinical and Experimental Nephrology

Experts’ opinion or the serotonin release assay as a gold standard for the diagnosis of heparin-induced thrombocytopenia (HIT)?

(2011) B. TARDY et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Incidence and clinical relevance of anti–platelet factor 4/heparin antibodies before cardiac surgery

(2010) Sixten Selleng et al.   AMERICAN HEART JOURNAL

Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia

(2010) N. L. Whitlatch et al.   BLOOD

Perioperative thrombocytopenia in cardiac surgical patients — incidence of heparin-induced thrombocytopenia, morbidities and mortality

(2010) Matthias Thielmann et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion

(2010) A. CUKER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Heparin/PF4 antibodies formation after heparin treatment: Temporal aspects and long-term follow-up

(2009) Anna Vittoria Mattioli et al.   AMERICAN HEART JOURNAL

The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia

(2009) N. Lubenow et al.   BLOOD

Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery

(2009) T. J. GLUCKMAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia

(2009) T. BAKCHOUL et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive

(2009) S. SELLENG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Post-operative platelet count profile: the most reliable tool for identifying patients with true heparin-induced thrombocypenia after cardiac surgery

(2009) Y. GRUEL et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Effectiveness of a new immuno-assay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies

(2009) C. Pouplard et al.   THROMBOSIS AND HAEMOSTASIS

Heparin-induced thrombocytopenia: a historical perspective

(2008) J. G. Kelton et al.   BLOOD

Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays

(2008) T. E. WARKENTIN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia

(2008) Tamas Alexy et al.   JOURNAL OF VASCULAR SURGERY

Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings

(2008) A. Greinacher et al.   THROMBOSIS RESEARCH